7:20 am Registration Opens

8:20 am Chair’s Opening Remarks

Delving Into IBD Subtyping to Improve Understanding of Molecular Pathways & Overcome Heterogeneity in Inflammatory Bowel Disease

8:30 am Reviewing the Pre-clinical Phase Inflammatory Bowel Disease to Understand the Underlying Mechanisms of Pathology


  • Reviewing of risk factors for IBD
  • Identifying the role of gut barrier function in Crohn’s disease onset
  • Highlighting the relationship between dietary and environmental influences prior to IBD onset to increase our understanding of preventative risk factors
  • Exploring omics profiling of pre-disease individuals to further understand the disease pathogenesis

9:00 am Integrating Gene Expression With Cellular & Tissue Level Profiling to Identify Patient Subtypes in IBD


  • Using molecular and cellular profiling we can classify IBD patients into subtypes based on the fine level biology of diseased tissue
  • Concurrent histopathology of the same samples shows these subtypes are linked to higher level tissue features including ulceration
  • Studying disease biology at the subtype level identifies subtype associated with patient response to current therapies and potential avenues for novel therapeutics

9:30 am Use of Stool-derived Eukaryotic RNA (seRNA) to Noninvasively Assess Patients with IBD


  • Improving detection, selection, and monitoring of treatment response for patients with IBD
  • Leveraging technology across a variety of biomarker types, including RNA expression, allele frequencies of expressed RNA variants, and protein concentrations
  • User-friendly platform allows periodic monitoring with improved patient engagement and compliance 

10:00 am Morning Break & Speed Networking

11:00 am Panel Discussion: Exploring More Objective Ways of Classifying IBD Subtypes to Improve Patient Stratification

  • Nicole Desch Principal Scientist - Translational Biomarker & Gastrointestinal Drug Discovery Lead, Takeda
  • Gerard Honig Director - Autoimmunity & Inflammatory Bowel Disease, Celsius Therapeutics
  • Olivier Laurent CSO, Prometheus Biosciences


A session dedicated to discussing the future of risk-classifying IBD patients and tackling the need for more objective classifications.

  • Discovering genetic signatures, microbiome patterns and proteomic indicators to formulate more homogenous patient groups to increase therapeutic efficacy within that patient group
  • Exploring novel scores to effectively measure burden of disease to better understand the patient need to inform therapeutic decisions
  • Addressing inconsistencies within the field regarding categorization of IBD subtypes to ensure novel discoveries are applicable across clinical settings

Optimizing IBD Diagnostics to Accelerate Prognosis & Early Intervention in IBD

11:45 am Differentiating Patient Subtypes to Improve Clinical Trial Design

  • James Canavan Executive Director - World Wide & Medical Affairs, Bristol Myers Squibb


  • Linking patient subtypes with underlying proteomic, genomic and microbial mechanisms to clinical trials, addressing the appropriate therapeutic target to improve therapeutic responses
  • Discussing novel biomarkers with the potential to advance IBD clinical trial design with a specific focus on informing inclusion and exclusion criteria
  • Identifying subtype specific disease monitoring markers to demonstrate drug efficacy and support treatment costs

12:15 pm Leveraging Biomarkers for Prognosis of Complicated Disease Course in Pediatric Crohn’s Disease

  • Andres Hurtado-Lorenzo Senior Director & Vice President - Translational Research & Inflammatory Bowel Disease, Ventures, Crohn’s & Colitis Foundation


  • Demonstrating the power of multi-omics and machine learning data analysis for biomarker discovery in support of precision medicine
  • Discussing the state of the art plasma proteomics platform for prognostic biomarker discovery
  • Exploring how such approaches can contribute towards prognosis of complicated disease course to enable early treatment decisions

12:45 pm Lunch Break & Networking

1:45 pm Reviewing Serological Markers to Predict Onset of IBD & Implications for IBD Understanding & Development of Preventative Strategies


  • Discussing the multi-omic approach of preclinical samples to predicting onset of IBD and identifying complex Crohn’s disease at diagnosis
  • Harnessing markers to identify main pathways of preclinical IBD
  • Discussing how these efforts could be expanded to other IMIDs and pave the way for preventative clinical trials

2:15 pm Identifying Clinically Relevant Molecular Programs in IBD


  • Using unsupervised single-cell analysis to reveal cellular determinants of inflammation
  • Inferring cell-to-cell interactions by combining spatial profiling with ligandreceptor analysis
  • Mapping high resolution molecular signatures to high-throughput clinical datasets

2:45 pm Panel Discussion: Assessing the Most Promising Advances in IBD Biomarkers


This is a session dedicated to evaluating the current use, future potential and limitations in a variety of not-yet clinically used biomarkers to get peer insights on the future of biomarkers for IBD and to discuss next steps in the field required for future advances.

Approaches to be discussed:

  • Utilizing metabolomics to profile IBD at scale
  • RNA sequencing – which sequences are the easiest to develop a marker from? How to demonstrate economic value of utilizing said sequences
  • Epigenetic biomarkers
  • Flow/Mass Cytometry
  • Transcriptomics and Proteomics

3:30 pm Afternoon Break & Networking

Stratifying Patients Based on Potential Drug Targets to Increase Therapeutic Efficacy

4:00 pm Defining Patient Populations for the Next Wave of IBD Treatments – The Janssen Approach


  • Where are we going and where are we today? From all comer populations to targeting differentiated patient populations – which role do molecular markers play and in which programs could they be critical?
  • Combination therapy development in IBD is behind other areas in medicine (e.g. HIV, hepatitis, oncology) – could molecular phenotyping help to advance these complex development programs in IBD?

4:30 pm Utilizing Single-Cell Analysis of IBD Patient Samples to Identify Disease-Driving Targets in Patient Subsets – Anti-TREM1 as an Exciting New Approach for IBD Patients


  • Discussing matching novel therapeutic interventions to patient subsets to improve individual patient outcomes
  • Identifying targetable disease-driving mechanisms in defined patients subsets through single-cell characterization of IBD tissue samples combined with clinical metadata
  • Exploring the potential of TREM1 inhibition to reset the pathological relationship between the immune system and intestinal bacteria in IBD

5:00 pm Identifying New IBD Drug Targets & Accompanying Patient Stratification Biomarkers From Large Multi-Modal Datasets


  • Discussing the importance and power of large multi-model datasets to identify new therapeutic targets in IBD
  • Reviewing Anti-TL1A and anti-CD30L precision medicine case studies to highlight the need for patient stratification
  • Identifying genomic variants as patient stratification biomarkers

5:30 pm Close of Conference Day 1

5:30 pm Drinks Reception